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IL- 10 induces IgG4 production in NOD- scid Il2rγnull mice 
humanized by engraftment of peripheral blood mononuclear 
cells
To the Editor,
IgG4 antibodies are considered to have anti- inflammatory activity and 
may confer protection against anaphylaxis and allergic inflammation. 
Strong increases in the production of allergen- specific IgG4 antibodies 
are frequently observed in allergic patients receiving allergen- specific 
immunotherapy (AIT).1 The production of IgG4 by human B cells in 
vitro is strongly enhanced by IL- 10.2,3 In vivo studies of the regulation 
of IgG4 have been handicapped by the fact that mice do not express 
this immunoglobulin isotype. As a result, conventional mouse models 
and gene- deficient or transgenic mice cannot be used to study aspects 
of the regulation of IgG4. The use of humanized mice allows the study 
of human immunoglobulin regulation including IgG4. Immunodeficient 
NOD.cg- Prkdcscid Il2rgtm1Wjl/SzJ (alternatively named NOD- scid Il2rγnull 
or NSG) mice lack murine lymphocytes, including T, B, and NK cells. This 
strain enables efficient engraftment of human hematopoietic progeni-
tor cells (HPC) and peripheral blood mononuclear cells (PBMC).4 While 
human lymphocytes engraft relatively well in NSG mice, there are cer-
tain limitations to this model, such as the low levels of human cytokines 
and growth factors present in serum and tissues, HLA incompatibility 
between engrafted lymphocytes and murine host cells, which will even-
tually culminate in graft- versus- host disease. Moreover, NSG mice have 
underdeveloped secondary lymphoid tissues. While engrafted human 
T and B cells populated lymph nodes and spleen, these tissues will not 
fully resemble human secondary lymphoid tissues.5 Nevertheless, 
this model has been successfully used to study allergen- specific T- cell 
responses.6 Here, we established a humanized mouse model to opti-
mize B- cell and plasma cell engraftment and to study the regulation of 
human immunoglobulin production in vivo.
To determine optimal conditions for B- cell engraftment in NSG 
mice, engraftment of human leucocytes after intraperitoneal (IP) and 
intravenous (IV) injections of 5x106 and 20x106 PBMC was analyzed 
after 14 and 21 days in spleen. Engraftment of human cells was deter-
mined by flow cytometry. Expression of human (hu)CD45 was used 
for gating of human leukocytes (Figure ). Successful engraftment of 
human cells was associated with increased spleen size (Figure S1). In 
control mice that did not receive PBMC, no huCD45+ cells were de-
tected (Figure 1A- D). Engraftment was not efficient (<1% huCD45+ 
splenocytes) for one out of 4 PBMC donors, and mice injected with 
these PBMC were excluded from the analysis. The percentages of 
huCD45+ cells ranged from 20% (in the 5 × 10E6 IV group) to 70% 
(in the 20 × 10E6 IV and 20 × 10E6 IP group) on day 14 and from 50% 
(5 × 10E6 IV group) to 90% (in the 20 × 10E6 IV group) on day 21 
(Figure 1B). The highest level of engraftment of huCD45+ cells was 
observed 21 days after IV injection of 20 × 106 PBMC. No signifi-
cant differences were found between the IV and IP groups in terms 
of total splenocyte counts and absolute numbers of huCD45+ cells 
(Figure 1B). Human B lineage cells (gated as huCD45+CD19+) were 
detectable at low levels on day 14 in the IV group and in both the IV 
and IP group on day 21 (Figure 1E,F). To differentiate between B cells 
and plasma cells, we gated B cells as CD19+CD138- (Figure 1E,G) 
and plasma cells as CD138+ (Figure 1E,H). Total CD19+ B lineage 
cells, CD19+CD138- B cells, and CD138+ plasma cells showed a 
similar pattern in which the highest level of engraftment, both as 
a percentage of huCD45+ cells and in absolute engrafted cell num-
bers, was observed with IV injection of 5 × 106 PBMC. The higher B 
lineage engraftment observed in the 5 × 106 IV group coincided with 
reduced T- cell frequencies (Figure 1I,J, Supplementary Figure 2A). 
Interestingly, the IV route of application was associated with a trend 
toward higher frequencies of CD4+ T- cell engraftment, while the 
IP route was associated with increased CD8+ T- cell frequencies 
(Figure 1J- L and Supplementary Figure 2B,C). The small fraction of 
CD3+CD4- CD8- cells (Figure 1I) may represent natural killer T cells 
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F I G U R E  1  Optimization of human lymphocyte engraftment in NSG mice. (A) Representative dot plots showing muCD45 and 
huCD45 staining in splenocytes of a mouse that did not receive PBMC and a mouse that was engrafted with human PBMCs. (B) Frequencies 
of huCD45+ cells in splenocytes of NSG mice 14 and 21 days after injection of 5 × 106 or 20 × 106 PBMC through IV or IP injection. (C) 
Total cell counts per spleen. (D) Total number of engrafted huCD45+ cells. (E) Left: Isotype control (i.c.) for CD19 and CD138, right: gating 
strategy for CD19+, CD19+CD138- and CD138+ cells. Dot plots show huCD45+ splenocytes. (F) Frequencies (left) and absolute numbers 
per spleen (right) of CD19+, (G) CD19+CD138−, (H) CD138+ cells. (I) Dotted line in histogram: isotype control (i.c.) for CD3. Bottom left dot 
plot: i.c. for CD4 and CD8. Bottom right: gating strategy for CD4+ and CD8+ T cells. Frequencies of (J) total CD3+ T cells, (K) CD4+ and (L) 
CD8+ T cells. *p < 0.05, **p < 0.01. Statistics were calculated using one- way ANOVA followed by Tukey's multiple comparison test. Graphs 
show mean ± SEM from three mice per group
F I G U R E  2  Administration of IL- 10 to humanized NSG mice results in elevated IgG4 production in vivo. (A) Gating strategy for gating of 
huCD45+, CD3+, CD19+,CD19+CD138−, and CD138+ cells. (B- F) Frequencies at 21 days after PBMC engraftment in spleens of human 
huCD45+ (B), CD3+ T cells (C), CD19+ B lineage cells (D), CD19+CD138- B cells (E), and CD19+CD138+ plasma cells (F). (G) Serum 
immunoglobulin levels measured 21 days after PBMC engraftment in mice treated with saline or IL- 10. Statistics were calculated using 
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P=0.68 P=0.20 P=0.54 P>0.99 P=0.43 P=0.59












































or γδ- T cells. We concluded that the IV route with 5x106 PBMC was 
optimal for B lineage and CD4+ T helper cell engraftment.
Next, we assessed the effect of IL- 10 on the B- cell compartment 
and immunoglobulin production. IP injection of 3 µg IL- 10 at day 3 and 
day 12 after PBMC engraftment did not significantly affect the en-
graftment of huCD45+ cells or CD3+ T cells (Figure 2A- C). The fre-
quencies of CD19+ cells were significantly reduced in the IL- 10- treated 
group (Figure 2D), while CD19+CD138- B cells (Figure 2E) and CD138+ 
plasma cell (Figure 2F) frequencies showed trends of reduction, with 
no statistically significant difference. All human immunoglobulin iso-
types were detectable in serum of IL- 10- treated or saline- treated con-
trol mice (Figure 2G). Interestingly, IL- 10 induced a significant increase 
in the serum level of IgG4, while no significant changes were observed 
for IgG1, 2, 3, IgM, IgA, and IgE. Macrophages are involved in the reg-
ulation of acquired immune responses in the spleen. Because IL- 10 is a 
known inhibitor of macrophage activation, it could be speculated that 
IL- 10 may affect different features of macrophages.
These data show that NSG mice can be used to efficiently en-
graft human B cells and plasma cells. However, it should be em-
phasized that this model has several limitations. Firstly, although 
human immunoglobulin isotypes are readily detectable in human-
ized NSG mice, murine Fcγ receptors have different affinities for 
human IgG subclasses than their human counterparts. Therefore, 
an increase in IgG4 might not be functional in future studies due 
to human aberrant or abrogated Fc fragment- murine Fc receptor 
interactions. We observed a relatively large degree of variation in 
human immunoglobulin levels between individual mice within the 
same treatment groups (Figure 2G). This may result from differ-
ences in the degree of plasma cell differentiation and survival or 
class switch recombination between individual mice. Such variations 
may impair the detection of subtle effects in more advanced studies 
involving antigen- specific responses. Moreover, it remains to be de-
termined whether allergen- specific B- cell and antibody responses 
can be efficiently induced in this model. Taken together, our findings 
demonstrate that human PBMC- engrafted NSG mice can be utilized 
to study human B- cell and immunoglobulin responses. 5X106 PBMC 
and application through IV injection were optimal for B- cell and 
plasma cell engraftment and IL- 10 treatment stimulated the in vivo 
upregulation of IgG4 production. In the allergy field, this model may 
be further developed to study in vivo antigen- specific B- cell and an-
tibody responses. It may be used to test novel AIT approaches, and 
combining this model with transfer of allergen- specific T- cell lines 
(as reported by Vizzardelli et al.)6 will allow in depth analysis on the 
effects of different T- cell subsets on B- cell and antibody responses.
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Clinical and genetic features of hereditary angioedema with 
and without C1- inhibitor (C1- INH) deficiency in Japan
To the Editor,
Hereditary angioedema with normal C1- inhibitor (HAEnCI) is an um-
brella term for several types of HAE that phenotypically resemble 
HAE but in which variants affecting function have been identified 
in genes other than the C1- INH gene (SERPING1).1 In contrast to 
European patients with HAE, we suppose comprehensive clinical 
and genetic data of HAE are scarcely reported from Asian countries, 
including Japan. In particular, HAEnCI in Asia has not been clearly 
characterized. Considering ethnic differences, it would be impor-
tant to clarify the features of HAE in the Asian population. Here, we 
report the clinical and genetic features of Japanese patients with 
158 cases from 122 families with HAE- C1- INH and 21 cases from 21 
families with HAEnCI. HAEnCI was defined as follows: normal C1- 
INH activity, no variants affecting function in the SERPING1 gene, 
at least one relative with recurrent angioedema attacks (i.e., positive 
family history), no history of urticaria, and lack of efficacy by anti- 
histamines or corticosteroids.
Table 1 shows clinical features of our Japanese patients with 
HAE- C1- INH and HAEnCI. When compared with HAE- C1- INH, 
HAEnCI was significantly more predominant among females (95.2% 
vs. 66.9%, p = .008), more frequently affected in the face (61.9% 
vs. 32.9%, p = .009) and pharynx/larynx (47.6% vs. 21.5%, p = .009), 
associated with more frequent exacerbations in the previous year 
(mean ± SD: 14.4 ± 27.3 vs. 3.66 ± 7.14, p = .0001), associated with 
higher prevalence of patients with more than six angioedema attacks 
in the previous year (52.4% vs. 16.5%, p = .0001), and more suscep-
tible to triggers such as physical stress (38.1% vs. 12.7%, p = .007) 
and upper respiratory infections (URI) (19.0% vs. 5.1%, p = .037). 
The prevalence of having a positive family history experiencing 
angioedema attacks was significantly higher in HAEnCI (100%) than 
in HAE- C1- INH (81.6%) (p = .027). This is because the inclusion cri-
teria of HAEnCI demand a family history of angioedema. There were 
no differences in most of the clinical features of male and female pa-
tients with HAE- C1- INH except the incidence of urological attacks 
and prodromal symptoms (Table S1).
It is of note that our patients with HAEnCI suffer from edema 
in the face and pharynx/larynx twice more frequently than those 
with HAE- C1- INH. In European patients with HAEnCI, facial and 
oropharyngeal swellings develop more predominantly than those 
with HAE- C1- INH as well.2 On the other hand, there are a number 
of differences in the clinical characteristics such as frequency of at-
tacks and triggers between Japanese and European patients with 
HAEnCI. In particular, hormonal perturbations induced by menstru-
ation/pregnancy or oral contraceptives did not seem to influence 
attacks in our patients with HAEnCI. This finding is in contrast with 
European patients with HAEnCI whose angioedema symptoms are 
frequently deteriorated by oral contraceptives or pregnancies.2
In the case of HAE- C1- INH, the incidence of abdominal at-
tacks was different between our patients and European patients. 
Abdominal attacks are common clinical manifestations of European 
patients with HAE- C1- INH, whose incidence reaches over 90% in 
these patients.3 In contrast, the proportion of patients who had 
experienced intestinal attack was 35.4% in our 158 patients with 
HAE- C1- INH (Table 1). Other reports from Asia such as the one from 
Mainland China4 have shown similar incidence of abdominal attacks 
with the present study.
Genetic analysis directed toward the entire exons for the known 
causative genes was performed for our Japanese HAEnCI patients 
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